Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Molecules (Basel, Switzerland)
|
May 13, 2018
Passive Aβ Immunotherapy: Current Achievements and Future Perspectives
Stephan Schilling, Jens-Ulrich Rahfeld, Inge Lues, et al.
Alzheimer'S Research & Therapy
|
June 8, 2017
Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer's disease patients
Claire Bridel, Torsten Hoffmann, Antje Meyer, et al.
International Journal of Molecular Sciences
|
November 13, 2021
Combination of the Glutaminyl Cyclase Inhibitor PQ912 (Varoglutamstat) and the Murine Monoclonal Antibody PBD-C06 (m6) Shows Additive Effects on Brain Aβ Pathology in Transgenic Mice
Torsten Hoffmann, Jens-Ulrich Rahfeld, Mathias Schenk, et al.
Scientific Reports
|
February 26, 2020
Development of the clinical candidate PBD-C06, a humanized pGlu3-Aβ-specific antibody against Alzheimer's disease with reduced complement activation
Thore Hettmann, Stephen D Gillies, Martin Kleinschmidt, et al.
The Journal of Biological Chemistry
|
June 18, 2017
Structural and functional analyses of pyroglutamate-amyloid-β-specific antibodies as a basis for Alzheimer immunotherapy
Anke Piechotta, Christoph Parthier, Martin Kleinschmidt, et al.
Alzheimer'S & Dementia (New York, N. Y.)
|
June 2, 2018
A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects
Inge Lues, Frank Weber, Antje Meyer, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
April 28, 2017
Glutaminyl Cyclase Inhibitor PQ912 Improves Cognition in Mouse Models of Alzheimer's Disease-Studies on Relation to Effective Target Occupancy
Torsten Hoffmann, Antje Meyer, Ulrich Heiser, et al.
Molecules (Basel, Switzerland)
|
April 21, 2018
Immunohistochemical Evidence from APP-Transgenic Mice for Glutaminyl Cyclase as Drug Target to Diminish pE-Abeta Formation
Maike Hartlage-Rübsamen, Alexandra Bluhm, Anke Piechotta, et al.
Neurobiology of Aging
|
October 11, 2015
An anti-pyroglutamate-3 Aβ vaccine reduces plaques and improves cognition in APPswe/PS1ΔE9 mice
Jeffrey L Frost, Bin Liu, Jens-Ulrich Rahfeld, et al.
Alzheimer'S Research & Therapy
|
October 13, 2018
Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study
Philip Scheltens, Merja Hallikainen, Timo Grimmer, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Molecules (Basel, Switzerland)
|
May 13, 2018
Passive Aβ Immunotherapy: Current Achievements and Future Perspectives
Stephan Schilling, Jens-Ulrich Rahfeld, Inge Lues, et al.
Alzheimer'S Research & Therapy
|
June 8, 2017
Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer's disease patients
Claire Bridel, Torsten Hoffmann, Antje Meyer, et al.
International Journal of Molecular Sciences
|
November 13, 2021
Combination of the Glutaminyl Cyclase Inhibitor PQ912 (Varoglutamstat) and the Murine Monoclonal Antibody PBD-C06 (m6) Shows Additive Effects on Brain Aβ Pathology in Transgenic Mice
Torsten Hoffmann, Jens-Ulrich Rahfeld, Mathias Schenk, et al.
Scientific Reports
|
February 26, 2020
Development of the clinical candidate PBD-C06, a humanized pGlu3-Aβ-specific antibody against Alzheimer's disease with reduced complement activation
Thore Hettmann, Stephen D Gillies, Martin Kleinschmidt, et al.
The Journal of Biological Chemistry
|
June 18, 2017
Structural and functional analyses of pyroglutamate-amyloid-β-specific antibodies as a basis for Alzheimer immunotherapy
Anke Piechotta, Christoph Parthier, Martin Kleinschmidt, et al.
Alzheimer'S & Dementia (New York, N. Y.)
|
June 2, 2018
A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects
Inge Lues, Frank Weber, Antje Meyer, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
April 28, 2017
Glutaminyl Cyclase Inhibitor PQ912 Improves Cognition in Mouse Models of Alzheimer's Disease-Studies on Relation to Effective Target Occupancy
Torsten Hoffmann, Antje Meyer, Ulrich Heiser, et al.
Molecules (Basel, Switzerland)
|
April 21, 2018
Immunohistochemical Evidence from APP-Transgenic Mice for Glutaminyl Cyclase as Drug Target to Diminish pE-Abeta Formation
Maike Hartlage-Rübsamen, Alexandra Bluhm, Anke Piechotta, et al.
Neurobiology of Aging
|
October 11, 2015
An anti-pyroglutamate-3 Aβ vaccine reduces plaques and improves cognition in APPswe/PS1ΔE9 mice
Jeffrey L Frost, Bin Liu, Jens-Ulrich Rahfeld, et al.
Alzheimer'S Research & Therapy
|
October 13, 2018
Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study
Philip Scheltens, Merja Hallikainen, Timo Grimmer, et al.
Page
of 2